Comparative Pharmacology
Head-to-head clinical analysis: DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE versus EMRELIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE versus EMRELIS.
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE vs EMRELIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxylamine succinate is a histamine H1 receptor antagonist with sedative properties; pyridoxine hydrochloride is a vitamin B6 derivative that acts as a coenzyme in amino acid, carbohydrate, and lipid metabolism. The combination is believed to reduce nausea and vomiting through central anticholinergic effects and pyridoxine supplementation.
Emrelis is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1 and PD-L2, thereby activating T-cell-mediated antitumor immune response.
1 tablet (doxylamine succinate 10 mg / pyridoxine hydrochloride 10 mg) orally twice daily (morning and evening), increased to three times daily if needed (one tablet in the morning, one in the afternoon, and two at bedtime). Maximum: 4 tablets per day.
100 mg subcutaneously once weekly.
None Documented
None Documented
Doxylamine: terminal half-life 10-12 hours; steady state reached in 3-4 days. Pyridoxine: half-life 15-20 days for body stores, but plasma half-life of pyridoxal phosphate ~15-30 minutes.
12 hours (terminal); dosing interval adjusted in renal impairment (CrCl <30 mL/min)
Doxylamine: ~60% renal as unchanged drug and metabolites; Pyridoxine: primarily renal as 4-pyridoxic acid and other metabolites. Up to 70% of pyridoxine metabolites excreted in urine within 24 hours.
Renal: 70% unchanged; fecal: 15%; biliary: 10%
Category C
Category C
Antiemetic
Antiemetic